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Background: Renal failure is one of the most serious complications associated with autosomal dominant polycystic
kidney disease (ADPKD). To date, early markers have failed to predict renal function deterioration at the early stages.
This 1-year prospective study evaluated N-acetyl-β-D-glucosaminidase (NAG) as a new surrogate marker for renal
function in ADPKD.
Methods: A total of 270 patients were enrolled in the study, and we measured urinary NAG, β2-microglobulin,
neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) prospectively for 1 year to
compare their predictive values for renal function.
Results: Baseline urinary NAG/Cr was negatively correlated with estimated glomerular filtration rate (GFR) (r2= 0.153,
P< 0.001) and positively correlated with total kidney volume (TKV) (r2= 0.113, P< 0.001). Among other biomarkers,
urinary NAG/Cr better discriminated patients with decreased renal function from those with conserved renal
function, showing the largest area under the curve (AUC 0.794). Immunohistochemical study revealed strong
staining along the cyst-lining epithelial cells as well as the nearby compressed tubular epithelial cells. However,
both single and repeated measurements of urinary NAG/Cr failed to predict renal function decline in 1 year.
Conclusions: Urinary NAG/Cr may be a useful surrogate marker for renal function in ADPKD patients.
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Autosomal dominant polycystic kidney disease (ADPKD)
is the most common hereditary renal disease. In
ADPKD, renal function deteriorates progressively as
cysts replace the renal parenchyma. However, cysts grow
significantly earlier than a decline in renal function is
observed [1]. Therefore, serum creatinine (sCr) and the
glomerular filtration rate (GFR) cannot properly reflect* Correspondence: nephro.hwang@gmail.com; curie@snu.ac.kr
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reproduction in any medium, provided the ordisease progression in ADPKD patients. Chapman et al.
demonstrated that total kidney volume (TKV) is a reli-
able surrogate marker for renal function in the early
stage of ADPKD [2]. However, imaging tools are imprac-
tical because they are time-consuming and expensive to
perform repeatedly. Therefore, there has been a growing
need for novel biomarkers that are easy, fast, and eco-
nomical to assess.
The N-acetyl-β-D-glucosaminidase (NAG) is a 130-kD
glycolytic lysosomal enzyme widely distributed among
different types of tissue cells [3]. In kidneys, NAG is
mainly distributed in the lysosome of the proximal con-
voluted tubules [4]. In previous studies, NAG has been
suggested to be elevated in various renal diseases and is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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renal tubular injury [5]. However, NAG has not been
thoroughly investigated in ADPKD patients. Therefore,
this 12-month prospective study was performed to
evaluate NAG as a potential surrogate biomarker for
renal function in ADPKD.
Methods
Study population
From 1984 to 2011, a total of 456 ADPKD patients were
registered at the Seoul National University Hospital
ADPKD clinic. ADPKD was diagnosed according to the
Unified Criteria for Ultrasonographic Diagnosis of
ADPKD proposed by Pei et al. [6]. Of the 456 ADPKD
patients, 270 were enrolled in this study after providing
informed consent. These patients were between 18 and
60 years in age and had estimated GFRs over 30 mL/
min/1.73 m2. The following patients were excluded:
those with acute illnesses, infections or acute kidney in-
jury within the past 3 months; patients with chronic ill-
nesses such as connective tissue disease, chronic
hepatitis, cancer, rheumatoid disease, or thyroid disease;
those with history of organ transplantation or nephrec-
tomy; those who have been maintained on renal replace-
ment therapy; pregnant women; and patients who either
refused to enroll in the study or to undergo imaging due
to contrast nephrotoxicity.
Data collection
Upon enrollment, information on age, gender, age at
diagnosis, family history (cerebro-vascular accident and
end-stage renal disease), co-morbidities (diabetes melli-
tus, coronary artery disease, heart failure, and peripheral
vascular disease), renal and extra-renal complications,
and duration of hypertension were collected. Follow-up
data were collected every 6 months. On each visit, sys-
tolic and diastolic blood pressures were measured. The
number and types of anti-hypertensive medications were
also reviewed. Laboratory parameters were collected
every 6 months. In addition, we reviewed the past med-
ical record to collect information on sCr and GFR at the
initial visit. The sCr was measured using the Jaffe
method. The GFR was calculated using both the isotope
dilution mass spectrometry (IDMS)-traceable Modifica-
tion of Diet in Renal Disease (MDRD) equation and
CKD-EPI (Chronic Kidney Disease Epidemiology) equa-
tion [7,8]. The mean follow-up duration after the first
visit was 11.0 ± 1.19 months.
Measurement of TKV
Instead of using MRI, we have evaluated TKV from re-
cent contrast-enhanced CT images. All patients under-
went three-dimensional contrast-enhanced CT of the
kidney and bladder using a multi-detector CT scanner.The CT examination was performed using a spiral tech-
nique with 3- to 5-mm thickness. Renal volume was
measured using the modified ellipsoid method [9]. The
TKV was defined as the sum of the left and right renal
volumes.
Measurement of urinary biomarkers
The activity of NAG was measured with a spectrophoto-
metric assay under a 340-nm wavelength using a TBA
200 FR biochemical analyzer (Toshiba, Tokyo, Japan)
[10]. To evaluate whether urinary NAG is the best mar-
ker of renal function and kidney enlargement, we also
measured other urinary biomarkers such as NGAL,
KIM-1, and β2-microglobulin. To measure urinary
NGAL and KIM-1, we separately collected 10 mL of
random spot urine samples in polypropylene bottles
containing 1 mL of 10 mM Tris buffer. Then, a 1-mL
aliquot of the sample was centrifuged at 3,000 x g for
10 minutes and stored at −70°C until the measurement.
Urinary NGAL and KIM-1 levels were measured using
an enzyme-linked immunosorbent assay (BioPorto Diag-
nostics, Denmark; R & D Systems, China). For NGAL
measurements, 1:100 diluted urine was used. The urin-
ary excretion level of β2-microglobulin was measured
using a β2-microglobulin radioimmunoassay kit by a
previously reported method (Beckman Coulter, Prague,
Czech Republic) [11]. To compensate for the production
of concentrated or dilute urine samples, the values of
NAG and β2-microglobulin were expressed based on
urinary creatinine content.
Immunohistochemistry of NAG
Formalin-fixed, paraffin-embedded polycystic and con-
trol kidney blocks were used for immunohistochemistry.
The procedures for the use of the human kidney speci-
mens were approved by Seoul National University Hos-
pital Institutional Review Board. The ADPKD kidney
specimen was obtained from a 47-year-old woman who
underwent right nephrectomy for renal cell carcinoma.
Her sCr level and eGFR prior to operation were
0.99 mg/dL and 60.12 mL/min/1.73 m2, respectively.
The control kidney used in this study was from a 70-
year-old man who underwent left nephrectomy for renal
cell carcinoma. His sCr level and eGFR prior to oper-
ation were 1.0 mg/dL and 58.3 mL/min/1.73 m2,
respectively.
Four-micron frozen tissue sections were prepared for
immunohistochemistry as described previously [12].
Primary antibody (Anti-MGEA5 rabbit monoclonal anti-
body, Epitomics, Burlingame, CA) was added at a dilution
of 1:450, followed by the addition of the secondary anti-
body (ZytoChem Plus HRP One-step Polymer anti-
Mouse/Rabbit/Rat, Zytomed System, Berlin, Germany).
The DAB substrate was given to reveal purple or brown
Table 1 Clinical characteristics of participants at
enrollment
Parameters Patients (N= 270)
Age (yr) 43.1 ± 9.6
Male 126 (46.7%)
Age at diagnosis (yr) 34.9 ± 9.5
Hypertension 208 (77.0%)
Duration of hypertension (yr) 7 (4–11)
Number of BP medication 2 (Min. 1, Max. 4)
Mean systolic/diastolic BP (mmHg) 130.2 ± 11.4/81.2 ± 8.3
Family history of ESRD 112 (41.5%)
Total kidney volume (mL) 1014 (Min 211, Max. 5324)
Hemoglobin (g/dL) 13.5 ± 1.53
Creatinine (mg/dL) 0.9 ± 0.3
IDMS-MDRD GFR (mL/min/1.73 m2) 85.0 ± 24.7




Data are expressed as numbers (percentages), mean ± SD, or median (Min.,
Max.). BP, blood pressure; CVA, cerebrovascular accident; ESRD, end-stage
renal disease.
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stained with hematoxylin (Surgipath Medical Industry,
Inc., IL, USA), viewed under an Olympus microscope
BX51, and photographed.
Statistical analyses
Analyses were performed using SPSS, version 19.0 (SPSS
Inc., www.spss.com) and R version 2.13.2 (www.r-project.
org). To investigate whether urinary biomarkers were cor-
related with either estimated GFR or TKV, linear regres-
sion analyses were performed. We also analyzed the
reference test as dichotomous variables to calculate re-
ceiver operating characteristic (ROC) curves. To adjust for
potential confounders, multiple regression analysis was
performed. The stepwise selection method was used to
define independent factors. Age, gender, hypertension,
urinary NAG/Cr, and the presence of albuminuria were
included in the final model.
This study was approved by the Institutional Review
Board of Seoul National University Hospital (H-0901-
046-269). Informed consent was obtained from the sub-
jects in accordance with the Declaration of Helsinki.
Results
Clinical characteristics of participants
The mean age of the patients was 43.1 ± 9.6 years, and
they were followed up in the ADPKD outpatient clinic
for a median of 60 (18–87) months at the time of enroll-
ment (Table 1). Hypertension was noted in 208 patients
(77.0%), and the mean systolic and diastolic blood pres-
sures were 130.2 ± 11.4 mmHg and 81.2 ± 8.3 mmHg, re-
spectively. The baseline sCr level was 0.9 ± 0.3 mg/dL
and the estimated GFR was 85.0 ± 24.7 mL/min/1.73 m2
(min. 30.0, max. 142.0) using IDMS-traceable MDRD
equation and 91.9 ± 23.3 mL/min/1.73 m2 using CKD-
EPI equation (min. 32.0, max. 134.0), respectively. The
TKV measured upon enrollment was 1014 mL (min.
211, max. 5324). The chronic kidney disease (CKD)
stage was defined according to the estimated GFR as
previously described [13]. The proportion of patients with
CKD stages II ~ IV increased over time, whereas the
proportion of patients with CKD stage I slightly decreased
over the same time period (See Additional file 1).
Correlation between TKV measured by modified ellipsoid
method and estimated GFR
Because we measured TKV by modified ellipsoid
method using CT images, we analyzed the association
between the measured TKV and estimated GFR before
performing other analyses. A total of 270 cases of CT
images were used to estimate TKVs. The TKV was log-
transformed prior to any analysis because it did not fol-
low a normal distribution. The TKV measured using CTimages was negatively correlated with the estimated GFR
(r2= 0.334, P < 0.001) (See Additional file 2).
Initial urinary NAG/Cr value is well correlated with the
subsequent urinary NAG/Cr measurements
To evaluate the stability of urinary NAG/Cr measure-
ment in each individual over time, we performed a linear
regression analysis between initial urinary NAG/Cr value
and subsequent measurements. The scatter plot demon-
strated a good correlation between initial urinary NAG/
Cr value with follow-up measurement at 6 months and
12 months (r2= 0.437 and 0.436, P < 0.001) (Figure 1).
Urinary NAG/Cr represents current estimated GFR and
TKV
A linear regression analysis was performed between the
estimated GFR and urinary biomarkers, including NAG/
Cr, β2-microglobulin/Cr, NGAL and KIM-1 (Figure 2).
Urinary NAG and β2-microglobulin levels were mea-
sured in 270 samples, NGAL levels were measured in
197 samples, and KIM-1 levels were measured in 64 sam-
ples. The age (43.4 ± 9.5 vs. 42.2 ± 9.9), gender (M/F =
95/102 vs. 31/42), and ACR (48.7 ± 88.3 vs. 58.3 ± 141.5)
did not vary significantly between those with and those
without NGAL measurements (P > 0.05). Among 270
patients with both NAG and β2-microglobulin measure-
ments, NAG/Cr and β2-microglobulin/Cr were nega-
tively correlated with the IDMS-traceable MDRD GFR
(r2= 0.153 vs. 0.033, P < 0.001). The estimated GFR
calculated by using CKD-EPI equation showed the
Figure 1 The association of urinary NAG/Cr levels from different time points. A linear regression analyses showed that the baseline urinary
NAG/Cr level was in a good correlation with subsequent urinary NAG/Cr measurements at 6 months and 12 months (r2= 0.437 and 0.436,
P< 0.001).
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Urinary NAG/Cr also showed a positive correlation with
TKV (r2= 0.113, P < 0.001). Although urinary β2-micro-
globulin/Cr exhibited a statistically significant correlation
with the estimated GFR, the Pearson’s correlation coeffi-
cient was smaller than that of urinary NAG/Cr. In
contrast, both NGAL and KIM-1 displayed no correl-
ation with any of the aforementioned parameters.
When we compared urinary NAG/Cr among patients
in different CKD stages according to IDMS-traceable
MDRD equation, the patients in CKD stage 3 (n = 116)
showed higher urinary NAG/Cr level compared to those
in CKD stage 1 (n = 109) or 2 (n = 45)(7.06 ± 3.9 vs.
3.7 ± 2.1 or 4.67 ± 2.5, P < 0.001)(See Additional file 3).
When we divided CKD stages using CKD-EPI equation,
the results were similar to that from IDMS-traceable
MDRD equation (data not shown).
To determine whether urinary NAG/Cr is a better indi-
cator of renal functional and structural markers than urin-
ary β2-microglobulin and NGAL, we performed a ROC
curve analysis. At first, urinary biomarker concentrations
were compared with the estimated GFR (the reference
procedures). Data from 197 baseline samples in which
NAG, β2-microglobulin and NGAL were measured were
included in the analysis. The sensitivity and specificity
were determined, and the area under the curve (AUC)
was calculated for the urinary NAG, β2-microglobulin and
NGAL levels. Among the other urinary biomarkers, urin-
ary NAG/Cr was a better indicator for discriminating
patients with decreased estimated GFRs (< 60 mL/min/
1.73 m2) from those with conserved renal function,showing the largest AUC (0.794) (Figure 3). The sensitivity
and specificity of urinary NAG/Cr was 75.2% and 81.2%,
respectively, with a cut-off value of 4.95 IU/g. The urinary
NAG/Cr was also a better indicator for discriminating
patients with enlarged kidneys (>1000 mL) from those
with smaller kidneys, showing the largest AUC (0.637).
Urinary NAG/Cr is an independent variable of estimated
GFR
In linear regression analyses (Table 2), age, years from
diagnosis, hypertension, degree of albuminuria, and
urinary NAG/Cr were associated with the estimated
GFR (P < 0.05). In multiple regression analyses, urinary
NAG/Cr remained as a significant risk factor after
adjusting for other variables (unstandardized coefficient,
95% CI; -4.5, -8.6 to −0.5, P= 0.03).
Single measurement of urinary NAG/Cr could not predict
renal function decline in 1 year
To elucidate whether a single measurement of urinary
NAG/Cr predicts ADPKD progression, we performed an
independent t-test to compare the mean values of 1)
baseline estimated GFR, 2) estimated GFR at 12 months,
3) absolute GFR change in 12 months, and 4) percentage
GFR change in 12 months between low and high
baseline urinary NAG/Cr groups (Figure 4). Low
(< 4.95 IU/g) and high (≥ 4.95 IU/g) NAG/Cr were
defined based on the cut-off value used in the previous
ROC curve analyses. Among the 164 patients with avail-
able follow-up samples at 12 months, 61 patients were











Figure 2 Linear regression analysis between each urinary biomarker and the IDMS-traceable MDRD GFR (left column), CKD-EPI GFR
(middle column), and TKV (right column). Biomarker concentrations and TKVs were log-transformed to fulfill the requirement of a normal
distribution of the residuals. Urinary NAG levels showed a better association with the IDMS-traceable MDRD GFR (r2= 0.153), CKD-EPI GFR
(r2= 0.194), and TKV (r2= 0.113) compared with other urinary biomarkers (P<0.001). NAG (A); β2-microglobulin (B); NGAL (C); KIM-1 (D). sCr, serum
creatinine; GFR, glomerular filtration rate; KIM-1, kidney injury molecule-1; NAG, N-acetyl-β-D-glucosaminidase; NGAL, neutrophil
gelatinase-associated lipocalin; TKV, total kidney volume.
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group (3.27 ± 1.1 IU/g). As the result, the high urinary
NAG/Cr group showed lower estimated GFR at baseline
(68.0 ± 24.6 vs. 92.6 ± 20.3 mL/min/1.73 m2, P < 0.001)
and at 12 months (53.3 ± 18.7 vs. 74.9 ± 18.0 mL/min/
1.73 m2, P < 0.001). However, the annual change of esti-
mated GFR was not significantly different in either
absolute value (−16.1 ± 11.6 vs. -19.6 ± 13.5 mL/min/
1.73 m2/yr, P= 0.08) or percentage change (−22.9% vs.-20.7%, P= 0.3) between high and low NAG/Cr groups.
Since the baseline estimated GFR may affect the subse-
quent GFR decline rate, we divided the patients into two
groups: estimated GFR ≥ 60 and < 60 mL/min/1.73 m2.
When we performed subgroup analyses, however, the an-
nual change of estimated GFR was not different between
high and low NAG/Cr groups. The results of our analysis
indicated that single measurement of urinary NAG/Cr
may not predict the renal function decline in 1 year.
Estimated GFR 
< 60 mL/min/1.73m2 
Total Kidney Volume 
> 1000 mL 
Figure 3 Receiver operating characteristic curve analysis with urinary biomarkers for estimated GFR<60 mL/min/1.73 m2 (A) and
TKV>1000 mL (B). Urinary NAG/Cr is a better marker for discriminating patients with decreased estimated GFRs (< 60 mL/min/1.73 m2) from
those with conserved renal function, showing the largest AUC (0.794). In addition, urinary NAG/Cr can best discriminate patients with enlarged
TKV (>1000 mL), showing an AUC of 0.637.
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indicate faster GFR decline in 1 year
Finally, we performed ANOVA to determine whether
persistently high level of urinary NAG/Cr is an indicator
of renal function deterioration (See Additional file 4). A
total of 161 patients with available baseline and 6- and
12-month data were included in the analysis. Patients
were divided into three groups based on serial measure-
ments of the urinary NAG/Cr over a 12-month period:
persistently low urinary NAG/Cr (<4.95 IU/g) (Group L-L,
n=78), variable urinary NAG/Cr (Group V, n= 54) and
persistently high urinary NAG/Cr (≥ 4.95 IU/g) (Group
H-H, n=29). The estimated GFR at baseline was signifi-
cantly lower in the Group H-H compared to the Group V
or the Group L-L (64.5± 23.3 vs. 77.6 ± 23.6 vs.
94.2 ± 19.8 mL/min/1.73 m2, P<0.001). In addition, the
estimated GFR at 12 month was significantly lower in the
Group H-H compared to the Group V or the Group L-L
(50.3 ± 18.5 vs. 63.0 ± 19.5 vs. 75.7± 18.0 mL/min/1.73 m2,Table 2 Linear regression analysis for risk factors for decreas
Parameters Univariable
B (95 % CI)
Age (yr) −1.4 (−1.6 to −1.1)
Gender 0.7 (−4.7 to 6.2)
Years from diagnosis −1.3 (−1.7 to −0.9)
Hypertension −23.4 (−29.2 to −17.6)
Albumin/Cr (mg/g) −9.3 (−11.7 to −7.0)
NAG/Cr (IU/g) −16.5 (−20.7 to −12.3)
Data were adjusted for age, years from diagnosis, hypertension and albuminuria. Al
normal distribution of residuals. Cr, creatinine; NAG, N-Acetyl-β-D-glucosaminidase.P<0.001). However, the percentage decrement of esti-
mated GFR was not different between groups (Group H-H
vs. Group V vs. Group L-L, -23.0% vs. -20.8% vs. -21.2%,
P=0.77). The results of our analysis indicated that
repeated measurement of urinary NAG/Cr may not predict
the renal function decline in 1 year.NAG is produced by both cyst lining epithelial cells and
compressed tubular epithelial cells in ADPKD
To elucidate the origin of NAG production in ADPKD
kidneys, we performed immunohistochemical stains
using an anti-MGEA5 antibody (Epitomics, Burlingame,
CA) (Figure 5). Compared with normal kidney tissue,
NAG was strongly stained upon the cyst-lining epithelial
cells and the proximal tubular epithelial cells. Moreover,
the proximal tubular epithelial cells that were com-
pressed by nearby cysts stained more strongly than non-
compressed normal tubules.ed estimated glomerular filtration rate
Multivariable
P value B (95 % CI) P value
< 0.001 −1.1 (−1.3 to −0.8) < 0.001
0.797 5.1 (0.7 to 9.5) 0.022
< 0.001 - -
< 0.001 −8.5 (−14.0 to −3.0) 0.003
< 0.001 −5.6 (−7.6 to −3.6) < 0.001
< 0.001 −4.5 (−8.6 to −0.5) 0.03





















Figure 4 Single measurements of NAG/Cr could not predict renal function deterioration in 1 year. As a whole, the patients with a high
baseline urinary NAG/Cr (≥ 4.95 IU/g) demonstrated lower estimated GFRs at baseline and at 12 months (54.8 ± 19.3 vs. 75.3 ± 18.7, P< 0.001).
However, annual decline of estimated GFRs were not different between high and low NAG/Cr groups. Subgroup analyses in the patients with
baseline estimated GFR≥ 60 and< 60 mL/min/1.73 m2 showed the similar results. Baseline estimated GFR (A); estimated GFR at 12 months (B);
annual change in GFR over 12 months (C); percentage decrement in 12 months (D).
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Our study suggests that the urinary NAG/Cr may repre-
sent a useful functional and structural marker in
ADPKD patients. A single measurement of urinary NAG
was well correlated with concurrent estimated GFR and
TKV. In addition, when compared with other urinary
biomarkers, urinary NAG levels showed a better associ-
ation with renal functional and structural markers.In fact, NAG has several advantages for use as a novel
biomarker. First, it is relatively stable with little diurnal
variation [14]. Second, it is a sensitive marker for tubular
damage. Subtle alterations in the epithelial cells in the
brush border of the proximal tubules result in shedding
of NAG into the urine, and the amount of shed enzyme
can be directly correlated to tubular injury [3]. Third,
NAG can be easily measured and quantified by
A B
C D
Figure 5 Immunohistochemisty staining of NAG. The NAG expression in ADPKD kidney. (A)~ (C) Anti-NAG antibody was strongly stained
along the cystic epithelial lining cells and adjacent compressed renal tubular epithelial cells. (D) NAG expression in normal kidney.
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renal tubular injury marker, has not been thoroughly
investigated in ADPKD patients.
Meanwhile, several factors have been suggested to
contribute to hypertension and renal failure in ADPKD.
First, Chapman et al. reported that decreased renal
blood flow (or increased vascular resistance) is an inde-
pendent predictor of renal function decline [2]. Another
study demonstrated morphological evidence of vascular
malformation using angiograms. The authors suggested
that neo-vascularization, which may be caused by cystic
compression of adjacent tissue, is a key factor for renal
progression [15]. Some investigators have suggested that
intrarenal activation of the renin-angiotensin system,
which is likely the result of renal ischemia, may play an
important role in disease progression [16,17]. Eckardt
et al. demonstrated increased erythropoietin formation
in interstitial cells juxtaposed with proximal tubular
cysts in ADPKD patients [18]. Results from these studies
point to the importance of ischemic insult and subse-
quent vascular remodeling in the disease progression of
ADPKD.
When we performed immunohistochemical staining of
NAG, staining was strongest along the cyst-lining epi-
thelial cells and the proximal tubular epithelial cells. In
particular, the cells that were compressed by nearby
cysts were more strongly stained than normal control
cells, suggesting that ischemic insult by cyst growth tothe adjacent tissue may be the key factor in the produc-
tion of NAG. Moreover, most of the enlarged cysts do
not have any connection with the original tubules, and
therefore NAG production from the cyst-lining epithelial
cells is less likely to contribute to the urinary NAG level.
Increased urinary NAG may be better explained by
NAG production from the nearby compressed tubules.
Therefore, urinary NAG may represent ongoing ische-
mic insult in ADPKD patients.
In our study, urinary NAG/Cr was correlated with
current TKV. We measured TKV by modified ellipsoid
method from CT images. Most previous studies mea-
sured TKV by computer-based volumetry using mag-
netic resonance imaging (MRI). We used CT images in
our patients because it is a more useful tool to diagnose
renal stones or obstructive uropathy and because it is
less expensive than MRI. The modified ellipsoid method
was developed to measure kidney volumes from ultra-
sonographic images. It underestimates TKV when com-
pared with MRI volumetry [19]. However, it is easy,
economical, and useful to evaluate renal enlargement in
serial measurements. Although the modified ellipsoid
method has not been used for CT images, our results
are comparable to that from the CRISP study (R =−0.54,
P < 0.001 vs. R =−0.37, P < 0.001). The correlation be-
tween urinary NAG/Cr and TKV was weaker than that
with the estimated GFR. The reasons for this remain to
be further elucidated, but one possible explanation is
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adequate to produce ischemic insults to the adjacent
tissue.
Previously, Meijer et al. investigated the role of NAG
in their cross-sectional study with 102 ADPKD patients
and 102 age- and sex-matched control subjects [20]. The
authors concluded that NGAL was the most useful mar-
ker for ADPKD disease progression. However, their
results should be interpreted cautiously because they
included relatively small number of patients and mainly
Caucasian. In addition, because we included patients
with relatively conserved renal function (IDMS-traceable
MDRD GFR 85.0 ± 24.7 vs. 68 ± 27 mL/min/1.73 m2)
and smaller TKVs (1014 [211–5324] vs. 1500 [900–
2200] mL) than Meijer’s population, the urinary NAG/
Cr may be the better marker to represent early disease
progression in ADPKD patients. Moreover, we demon-
strated the possible link between cyst growth and pro-
nounced NAG production from compressed tubules.
Therefore, urinary NAG/Cr may be more useful surro-
gate marker for renal function that shows underlying
pathogenesis of ADPKD disease progression.
Unfortunately, our study failed to prove the role of
urinary NAG/Cr in the prediction of renal function de-
terioration in 1 year. In our study, both single and
repeated measurements of urinary NAG/Cr were not
able to predict a decline in the estimated GFR. However,
the patients with higher baseline NAG/Cr (≥ 4.95 IU/g)
showed relatively higher annual percentage decrement
in estimated GFR (−22.9% vs. -20.7%, P = 0.3). In
addition, the persistently high NAG/Cr (Group H-
H ≥ 4.95 IU/g) group showed higher annual percentage
decrement in estimated GFR compared to the other
groups (Group H-H vs. Group V vs. Group L-L, -23.0%
vs. -20.8% vs. -21.2%, P= 0.77). Our findings are in the
same context with the results from the recent 3-year
prospective study demonstrated by CR Parikh et al. [21].
They showed both urinary Il-18 and NGAL levels were
elevated in ADPKD but did not correlate with worsening
in kidney function or increase in TKV. Since the natural
course of ADPKD is indolent in the early stage, 1 year of
follow-up seems too short to evaluate the renal function
decline in our cohort. Moreover, the effect of baseline
estimated GFR is too strong to see the independent ef-
fect of urinary NAG/Cr upon the subsequent renal func-
tion decline. Therefore, we assume that longer period of
follow-up time is necessary to evaluate the rate of renal
function decline.
This is the first 1-year prospective study demonstrat-
ing the usefulness of urinary NAG/Cr as a surrogate
marker for renal function in ADPKD. To the best of our
knowledge, our study evaluated the largest ADPKD co-
hort to date for a urinary biomarker study. However, our
study has a few limitations. This is a single-center studythat included only Korean patients. Second, we excluded
patients in advanced CKD stages. Therefore, further
large-scale studies should be conducted to extend our
results to other populations. Third, we measured TKV
using a modified ellipsoid method from CT images. Al-
though our results are comparable with CRISP results,
validation is needed to using this method in CT volume-
try. Finally, long-term follow-up data should be analyzed
later to determine whether urinary NAG is useful in the
prediction of renal function decline.
Conclusions
In conclusion, we found that high urinary NAG/Cr was
associated with lower estimated GFR and larger TKV.
Further long-term studies should reveal the usefulness
of urinary NAG/Cr in the prediction of faster renal func-
tion deterioration.
Additional files
Additional file 1: Patient distribution according to chronic kidney
disease stages. The proportion of advanced CKD stages (IIIB and IV)
increased as time passed.
Additional file 2: Linear regression analysis between the estimated
glomerular filtration rate and total kidney volume. The TKV was
negatively correlated with the estimated GFR (r2= 0.334, P< 0.001).
Additional file 3: Urinary NAG/Cr according to chronic kidney
disease stages. Patients in chronic kidney disease (CKD) stage III
(estimated GFR < 60 mL/min/1.73 m2) showed significantly higher urinary
NAG/Cr compared with CKD stage I or II (6.48 ± 3.79 vs. 3.7 ± 2.13 vs.
4.67 ± 2.47, P< 0.001).
Additional file 4: Repeated measurements of NAG/Cr could not
predict renal function deterioration in 1 year. The patients were
divided into three groups according to serial measurements of urinary NAG/
Cr: persistently low NAG/Cr (<4.95 IU/g) (Group L-L), variable NAG/Cr (Group
V), and persistently high NAG/Cr (≥4.95 IU/g) (Group H-H). Group H-H
showed lower estimated GFRs at baseline (64.5± 23.3 mL/min/1.73 m2) and
lower estimated GFR at 12 month (50.3 ± 18.5 mL/min/1.73 m2) compared
to other groups (P<0.001). Although statistically insignificant, the
percentage decrement of estimated GFR over 12 months were greater in
Group H-H compared to the other groups (Group H-H vs. Group V vs. Group
L-L, -23.0% vs. -20.8% vs. -21.2%, P=0.77).
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